Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
|Articles|October 15, 2021
Daily Medication Pearl: Risankizumab-rzaa (Skyrizi) for Plaque Psoriasis
Author(s)Saro Arakelians, PharmD
Risankizumab-rzaa treats moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Advertisement
Medication Pearl of the Day: Risankizumab-rzaa (Skyrizi)
Indication: Risankizumab-rzaa is an interleukin (IL)-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Insight:
- Dosing: 150 mg administered by subcutaneous injection at week 0, week 4, and every 12 weeks thereafter.
- Dosage form: Injection 150 mg/mL in each single-dose prefilled pen. Injection 150 mg/mL in each single-dose prefilled syringe. Injection 75 mg/0.83 mL in each single-dose prefilled syringe.
- Adverse events (AEs): Most common AEs (≥ 1%) are upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.
- Mechanism of action: Risankizumab-rzaa is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds to the p19 subunit of the IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.
- Manufacturer: Abbvie
Sources:
Advertisement
Related to this article
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
2
Two Gene Therapy Approvals Expand Options for Rare Immune Disorders as Access Challenges Persist
3
Is Less More? Comparing Metronidazole Dosing in Confirmed Anaerobic Infections
4
RSV Hospitalization Linked to Higher Short-Term Risk of Invasive Pneumococcal Disease
5